MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Inhibiting transgene expression with a tissue-specific microRNA target ameliorates AAV vector toxicity in NHPs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These results further suggest that the differences in signalling observed between CAG and hAAT-carrying vectors in vitro are due to expression of the transgene similar to what has been reported in the context of DRG toxicity 38 .”
From AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain (2025) · cites this paper as [38]
In the citing paper
“Previous work has suggested a role for transgene over-expression in DRG toxicity 38 .”
From AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain (2025) · cites this paper as [38]
In the citing paper
“possibility of alternative, non-immune-mediated toxicity such as dorsal root ganglion toxicity with AAV9 (110)”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [110]
In the citing paper
“For example, AAV-mediated gene delivery into the CNS of pigs or non-human primates causes dorsal root ganglion toxicity that is alleviated by reducing or deleting transgene expression.38,39,66”
From An innate immune response to adeno-associated virus genomes decreases cortical dendritic complexity and disrupts synaptic transmission (2024) · cites this paper as [39]
In the citing paper
“Despite an overall strong safety profile, AAV-mediated gene delivery has been associated with neurotoxicity in specific cell populations, some of which can be attributed to the overexpressed transgene.”
From An innate immune response to adeno-associated virus genomes decreases cortical dendritic complexity and disrupts synaptic transmission (2024) · cites this paper as [39]
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Raper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G.-P., Wilson, J. M., & Batshaw, M. L. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.016 · Cited by 1,498
Self-citationClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 1×
“At the turn of the century, researchers found a family of endogenous AAVs that, as vectors, achieved much higher transduction efficiencies while retaining favorable safety profiles (2).”
BackgroundSelf-citationDistribution of miRNA expression across human tissues
Ludwig, N., Leidinger, P., Becker, K., Backes, C., Fehlmann, T., Pallasch, C., Rheinheimer, S., Meder, B., Stähler, C., Meese, E., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw116 · Cited by 968 · cited 1×
“Under normal conditions, expression of this complex is largely restricted to neurons of the olfactory epithelium, ear, retina, and DRG as demonstrated in zebrafish (23), mouse (24–26), rat (27), and human tissues (24, 28).”
BackgroundHinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814
Self-citationHoggan, M. D., Blacklow, N. R., & Rowe, W. P. (1966) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.55.6.1467 · Cited by 536
Brown, B. D., Venneri, M. A., Zingale, A., Sergi, L. S., & Naldini, L. (2006) · Nature Medicine · doi:10.1038/nm1398 · Cited by 484 · cited 1×
“We used an approach previously deployed for restricting lentiviral vector expression in hematopoietic-derived cells (20) or detargeting the liver, heart, or muscle after AAV-mediated gene transfer (21, 22).”
Method
Research works printed but not linked: 2
- Pfizer (2019); https://investors.pfizer.com/investor-news/press-release-details/2019/Pfizer-Presents-Initial-Clinical-Data-on-Phase-1b-Gene-Therapy-Study-for-Duchenne-Muscular-Dystrophy-DMD/default.aspx.
- V. Kumar A. K. Abbas J. C. Aster Robbins and Cotran Pathologic Basis of Disease (Elsevier Saunders Philadelphia 2015) pp. 31–68.
Cited by
Items 101–170 of 170
Assuring long-term safety of highly effective gene-modulating therapeutics for rare diseases
Crawford, T. O., & Sumner, C. J. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152817 · Cited by 8
Song, C., Wang, Q., Zhu, P., Li, J., Dai, L., Hu, W., Yang, W., Zhang, R., Wang, D., Li, Z., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101475 · Cited by 7
Self-citationNagy, M. A., Price, S., Wang, K., Gill, S., Ren, E., Jayne, L., Pajak, V., Deighan, S., Liu, B., Lü, X., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2418024121 · Cited by 7
“…events in nonhuman primate (NHP) AAV pre-clinical studies, including dorsal root ganglion (DRG) mononuclear cell infiltration and sensory neuron degeneration following systemic or intrathecal AAV administration, presumably due to high off - target transgene expression in this cell type ( 13 – 16 ).”
Wang, Y., Zhang, W., Yip, H., Qu, C., Hu, H., Chen, X., Lee, T., Yang, X., Yang, B., Kumar, P., et al. (2023) · Patterns · doi:10.1016/j.patter.2023.100686 · Cited by 8
Efficacy and muscle safety assessment of fukutin-related protein gene therapy
Benasutti, H., Maricelli, J. W., Seto, J. T., Hall, J. K., Halbert, C. L., Wicki, J., Huesgen, L., Purvis, N., Regnier, M., Lin, D. C., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.05.022 · Cited by 7
Toxicologic Neuropathology of Novel Biotherapeutics
Bangari, D. S., Lanigan, L. G., Cramer, S. D., Grieves, J. L., Meisner, R., Rogers, A. B., Galbreath, E. J., & Bolon, B. N. (2023) · Toxicologic Pathology · doi:10.1177/01926233241230542 · Cited by 7
“Potential mechanisms of neurotoxicity include immunogenicity of the transgene or viral proteins, 53,143 cell exhaustion resulting from protein overexpression, 77 and toxicity of the transgene product.”
BackgroundRao, D. B., Pardo, I. D. R., Chang, J., Bolon, B. N., & Garman, R. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-821046-8.00007-4 · Cited by 8
Yuan, W., Liu, W., Zhan, X., Zhou, Y., Ma, R., Liang, S., Wang, T., & Ge, Z. (2023) · Neuroreport · doi:10.1097/wnr.0000000000001912 · Cited by 8
Higuchi, T., Shimada, Y., Takahashi, Y., Kato, F., Ohashi, T., & Kobayashi, H. (2024) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2024.108545 · Cited by 6
Liu, W., Rao, X., Sun, W., Chen, X., Yu, L., Zhang, J., Chen, J., & Zheng, X. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05164-0 · Cited by 7
“Viral vector-mediated delivery can induce miRNA expression within the CNS, offering targeted gene regulation [143, 144].”
Commentary: Current Status of Gene Therapy for Spinal Muscular Atrophy
Rossoll, W., & Singh, R. N. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.916065 · Cited by 6
Optogenetics: Pinpoint Light on Precise Neuromodulation
Guo, J., Yeung, K., Jiang, C., Duan, L., Han, X., & Qiao, W. (2025) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2025.3624697 · Cited by 5
“…miRNA detargeting strategies using tissue-specific miRNA sites in transgene cassettes can decrease expression in peripheral organs, mitigate transgene-related toxicity, and suppress immune responses, thereby ensuring the safety and specificity of AAV-based gene therapies [139], [140], [141].”
Grubor, B., Henry, K. L., Chan, S. J., Sheehan, M. J., Shah, A., Pellerin, A., Bai, J., Nadella, P., Bommegowda, S., Cullen, P. F., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101643 · Cited by 6
“Yet , previous reports, 3,23 as well as data presented herein, strongly support a role for transgene expression in AAV-mediated DRG toxicity in NHPs. Consistent with a role for transgene expression, our transcriptomic analysis demonstrates that the late transcriptional changes in DRGs on days 15…”
InfluentialViral vectors for gene delivery to the central nervous system
Ingusci, S., Hall, B. L., Goins, W. F., Cohen, J. B., & Glorioso, J. C. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90120-8.00001-0 · Cited by 8
Dose escalation pre-clinical trial of novel DOK7-AAV in mouse model of DOK7 congenital myasthenia
Cossins, J., Kozma, I., Canzonetta, C., Hawkins, A., Beeson, D., Sepulveda, P. V., & Dong, Y. Y. (2024) · Brain Communications · doi:10.1093/braincomms/fcaf046 · Cited by 6
González, A. B., Sánchez, Á., Rodríguez, I., del Rey, J., Lope‐Piedrafita, S., Prat, E., Nunes, V., Chillón, M., Estévez, R., & Bosch, A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.046 · Cited by 5
“66,67 Here, therapeutic vectors were administered at a dose of 3.2 (cid:4) 10 13 vg/kg, a value which lies significantly below the threshold that previous gene therapy assays have demonstrated to be toxic to mice, nonhuman primates (NHPs), or even humans.”
InfluentialMa, W., Wu, Z., Zhao, T., Xia, Y., Qin, J., Tian, X., Li, X., He, J., Zhang, Y., Zhang, L., et al. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01207-4 · Cited by 6
Samie, M., Parman, T., Jalan, M., Lee, J., Dunn, P., Eshleman, J. A., Vidales, D. B., Kennard, K., Holter, J., Jones, B., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adu0217 · Cited by 5
Fischer, S. E., Strobel, B., Weinmann, J., & Gillardon, F. (2021) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2021.109457 · Cited by 6
Farrar, M. A., Groen, E. J. N., & Alves, C. R. R. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.06.005 · Cited by 5
Current neuroprotective therapies and future prospects for motor neuron disease
Evans, L. J., O’Brien, D., & Shaw, P. J. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.04.003 · Cited by 5
The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art
Minno, G. D., Spadarella, G., Calcaterra, I. L., Castaman, G., Simioni, P., CRISTOFARO, R. D., Santoro, C., Peyvandi, F., & Minno, M. N. D. D. (2024) · Bleeding Thrombosis and Vascular Biology · doi:10.4081/btvb.2024.144 · Cited by 4
Dou, D., Lu, J., Chen, X., & Zhang, X. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03931-2 · Cited by 4
“The incorporation of DRG-specific miRNA binding sites in the 3' UTR facilitates the downregulation of transgene expression in DRG, thereby preventing AAV pathogenic damage in non-human primates [86].”
Chen, S., He, B., Singh, S., & Martin, N. P. (2023) · Neuromethods · doi:10.1007/978-1-0716-2918-5_6 · Cited by 6
Lafora disease gene therapy: EPM2A but not EPM2B overexpression results in Lafora body formation
Alao, E. D., Sheibani, M., Wu, J., Marriam, U., Evans, D., Kasiri, S., Verma, M., Nitschke, S., Nitschké, F., Gray, S. J., et al. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e00866 · Cited by 5
“These could include a feedback-regulated construct [58], such as is in clinical trial presently for Rett syndrome, or constructs regulating expression in the most susceptible cells (DRG) as previously published [59].”
Safety of Onasemnogene Abeparvovec Administration to Type 1 SMA Patients Who Have Received Risdiplam
Chelladurai, S., D’Urso, S., Atherton, M., & Ong, M. T. (2025) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0000000000000521 · Cited by 3
Reducing AAV vector associated neurotoxicity
Crunkhorn, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00209-7 · Cited by 3
Chai, S., Kim, Y., Galivo, F., Dorrell, C., Wakefield, L., Posey, J., Ackermann, A. M., Kaestner, K. H., Hebrok, M., & Grompe, M. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.219 · Cited by 5
“36 In this study, the beta cell specificity improved with the addition of increasing numbers of alpha cell-targeted MREs.”
AAV Immunotoxicity: Implications in Anti-HBV Gene Therapy
Jacobs, R., Dogbey, D. M., Mnyandu, N., Neves, K., Barth, S., Arbuthnot, P. B., & Maepa, M. B. (2023) · Microorganisms · doi:10.3390/microorganisms11122985 · Cited by 3
“A recent study demonstrated that AAVs bearing dorsal root ganglion (DRG)-specific miR targets in the 3 (cid:48) untranslated region of the transgene mRNA can mitigate AAV-associated DRG toxicity without affecting transduction in other parts of the brain [162].”
BackgroundAAV-RNAi constructs promote DRG toxicity
Xie, J., & Tai, P. W. L. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.027 · Cited by 2
Sleep Disorders in Neurodegenerative Diseases: Pathological Correlations and Underlying Mechanisms
Wang, Z., He, F., Li, L., Wang, W., Zhang, L., Tang, J., & Le, W. (2026) · Neuroscience Bulletin · doi:10.1007/s12264-026-01609-2 · Cited by 3
“However, challenges, including limited blood-brain barrier penetration and immune responses, have impeded clinical translation [215].”
Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives
Yang, M., Song, Y., Wang, Z., Chao, K., Li, L., Zhang, X., Duan, X., Yu, C., Xue, R., & Zhao, J. (2026) · MedComm · doi:10.1002/mco2.70791 · Cited by 5
Rubin, J. D., Ayasoufi, K., McGlinch, E. B., Hansen, M. J., Harris, P. C., Torres, V. E., & Barry, M. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.28.656514 · Cited by 2
“Although increasing transduction in tubule cells in the kidney is an important goal for efficacy of gene therapy, detargeting vectors from off-target tissues is an important facet of gene therapy safety 21,22 .”
Next-generation enhancer AAVs for selective interspecies targeting of midbrain dopaminergic neuronsPreprint
Caplan, K. A., Chen, K., Wienisch, M., Wang, Y., Chai, R., Kang, I.-H., Chen, C. S., del Rosario, R. C. H., Krienen, F. M., Wang, F., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.06.687071 · Cited by 2
Aihara, F., Mardo, M., Ruda, V. M., del Rio, T., Bigot, K., Singer, J., Onishi‐Seebacher, M., Couttet, P., Mansfield, K., & Hudry, E. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101617 · Cited by 2
Species barriers in AAV tropism: mechanisms, models, and emerging solutions for clinical translation
Xu, X. (2026) · Acta Biochimica Polonica · doi:10.3389/abp.2026.15939 · Cited by 2
Challenging the more-is-better dogma: A precision-optimized AAV gene therapy for SMA
Song, C., Liu, J., Wang, Q., Zhu, P., Xu, J., Zhou, Y., Lin, Z., Xin, X., Hu, W., Li, Z., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.027 · Cited by 2
“12,13 In the context of SMA, clinical dose of onasemnogene abeparvovec is 1.1 × 10 14 vg/kg; however as reported, modestly higher dose levels in the preclinical evaluations were associated with dose-dependent toxicities: in mice, administration at doses equal to or higher than 2 × 10 14 vg/kg…”
InfluentialSelf-citationSensory neuronopathy secondary to gene therapy with AT845 for Pompe disease
Pena-Guzman, L., Bolano-Diaz, C., Lleixà, C., Querol, L., Trainor, C., Suetterlin, K., Straub, V. W., & Díaz‐Manera, J. (2026) · Neuromuscular Disorders · doi:10.1016/j.nmd.2026.106441 · Cited by 1
Amaral, A. C. S., Grubor, B., Gianni, D., Koetzner, L., Abraham, N., Bourque, S., Brown, D. C., Chen, Y., Chicoine, K.-E., Clarner, P., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201779 · Cited by 1
Tessier, M., Hamzé, Z., Bonello‐Palot, N., Roëckel, N., Silva, N. D., Verlet, I., Broucqsault, N., Bertaux, K., Delmont, É., Attarian, S., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2530774123 · Cited by 1
Biomarker and Bioanalytical Readouts for the Development of AAV Gene Therapy
Lu, Y., & Lembke, W. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch3 · Cited by 1
Brain-wide Genome Editing via STEP-RNPs for Treatment of Angelman SyndromePreprint
Lu, X., Xie, Y., Bao, Y., Yu, J., Wang, Z., Fan, J., Sheu, W. C., Long, G., Tu, Z., Tong, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.13.684643 · Cited by 1
A Cautiously Optimistic Outlook of a Designer Therapy for 1% of Duchenne Muscular Dystrophy Patients
Duan, D. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.29179.ddu
A Brillouin spectroscopic study of the I-II phase transition in CH₄
Kelly, R. (1992) · Memorial University Research Repository (Memorial University)
Assaf, B. T., Harper, C. G., & Phillips, J. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00034-8 · Cited by 2
Intrathecal Delivery of Viral Vector-Mediated Gene Therapy
Keifer, O. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-39558-1_16
Adeno-associated virus-mediated gene therapy in central nervous system genetic disorders
Ling, Q., Boitnott, A., Garza, I. T., Casy, W., Shaffo, F. C., Sinnett, S. E., & Gray, S. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00007-8
Even a Worm Will Turn: Immunity Following AAV Vector Administration
Patel, K., Khatri, A., & Somanathan, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-62007-2_7
Preclinical development of viral vector gene therapies
Newman, M. S., Hudry, E., Brassard, J. A., & Cunningham, J. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13344-2.00003-1
Nucleic Acid-Based Systems for Regenerative Medicine
Martín, L., & Grzela, D. P. (2025) · Springer eBooks · doi:10.1007/978-3-031-87744-5_8 · Cited by 1
Gene therapy-mediated overexpression of wild-type MFN2 improves Charcot-Marie-Tooth disease type 2APreprint
Tessier, M., Hamzé, Z., Bonello‐Palot, N., Roëckel, N., Attarian, S., Bartoli, M., Delague, V., Schneider, B. L., & Bernard‐Marissal, N. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.15.682364
An AAV-Based Therapy Approach for Neurological Phenotypes of X-Linked Adrenoleukodystrophy
Gornostal, E. A., Alsalloum, A., Degtyarev, E., Kuznetsova, E., Levashova, A., Mishina, D., Mingaleva, N., Mazloum, A., Bogdanov, V. P., Krupinova, J. A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311645
“A further concern associated with both intra-CSF and IV AAV administration is dose-dependent toxicity within the sensory neurons of DRG and peripheral nerves [94,96,148,149].”
InfluentialDeciphering the role and contribution of AAV immune responses to DRG toxicity
Hordeaux, J., & Chan, Y. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201675
“6 These findings suggest that strategies aimed at reducing the transduction burden in DRG, such as lowering the overall vector dose, using weaker or tissue-restricted promoters, or us-ing DRG-specific regulatory elements, may offer safer and more clinically relevant solutions than non-specific IS.”
Self-citationAdeno-associated virus-induced neurotoxicity is prevented by CpG depletion
Dunn, C. E., Carvajal, B. V., Ma, J., Castaneda-Hernandez, G., Nguyen, A. V., Jung, C., Suriano, C. M., & Boulanger, L. M. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201703 · Cited by 1
“40 Although some of these neurotoxic effects of AAV are thought to reflect non-immune mechanisms, including transgene toxicity, 39,41 for others the mechanisms remain unclear.”
Microphysiological systems to accelerate and de-risk AAV gene therapy development
Tornabene, P., Berreur, E., Roth, A., & Kasendra, M. J. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115841
Chen, X., Xie, Q., Nath, S. J., Tang, M., Ma, H., Günes, Y. Ö., Sharma, T., Liu, H., Cui, M., Du, A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73545-8
“Although neurological toxicity was not observed in the SMA mice treated with the 2nd-generation vector, the motor function decline and hind-limb clasping in WT mice suggestthatexcessiveSMNexpressionintheCNSandDRGscouldbea concern for long-term health.”
InfluentialPathophysiology and biomaterials based therapeutic strategies for spinal muscular atrophy
Nasser, A. A., Nasser, R. A., Singh, H., Veettil, R. M., Tuffaha, M., Oueis, E., Pitsalidis, C., Ashraf, S. M., Athamneh, K. N., & Hassan, S. (2026) · In vitro models · doi:10.1007/s44164-026-00123-z
“In the nervous system specifically, high-dose systemic or direct cerebrospinal fluid delivery of AAVs has been shown to induce severe off-target neuronal damage in the form of dorsal root ganglion (DRG) toxicity [63].”
Russell, K. A., Shahrabi, A. A., Akerman, S. C., Byrne, M. D., Rothstein, J. D., Trotti, D., Jensen, B. K., & Haeusler, A. R. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02341-8
“Higher AAV doses may amplify reported phenotypes but must be approached cautiously, as they can induce inflammation or toxicity [86–89], and consideration of serotype, promoter, and route of delivery would be necessary to mitigate off-target effects [50,90– 92].”
Zhou, Y., Diao, Y., Yan, Z., Shui, X., Huang, Z., Sun, Y., Wang, S. W., Xia, Y., Lee, T. H., & Wang, L. (2026) · Biomolecules · doi:10.3390/biom16081075
“A combination of AAV vectors and miRNA therapeutics has been demonstrated to reduce neuronal toxicity in primates [82].”
Hawley, Z. C. E., Guise, A. J., Pardo, I. D. R., Chowdhury, T., Hana, S., Zavodszky, M. I., Engle, L., Wiltberger, K., Bartlett, D., Raitcheva, D., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201818
Wang, F., Wang, L., Xu, Z. Y., 欧泽群, Yun, W., Haiying, Y., Fei, J., Song, J. H., Chen, Y., & Lv, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1899891
“Furthermore, adeno-associated virus (AAV) vector-mediated delivery introduces risks of hepatotoxicity, as high-dose systemic AAV administration has been associated with signi fi cant liver injury in both preclinical models and clinical gene therapy trials (131).”
Orbach, R., Gil-Garzon, M. R., Büning, H., Bönnemann, C. G., Muntoni, F., Bönnemann, C. G., Büning, H., Assaf, B. T., Beaverson, K., Braun, S., et al. (2026) · Neuromuscular Disorders · doi:10.1016/j.nmd.2026.107371
Self-citationRougvie, M. D. M., Kebret, M. R., Wu, Y., Stiles, K. M., & Crystal, R. G. (2026) · Human Gene Therapy · doi:10.1177/10430342261457812
“…a prodrug is administered, 23 embedding organ-speci fi c miRNAs in the therapeutic expression cassette to prevent transgene product-mediated toxicity 24 or tunning the expression, limited attention has been directed to suppressing AAV-mediated gene expression in response to an adverse effect…”
Clinical immunogenicity in rAAV gene therapy: Insights and implications
Gulve, N., Bego, M. G., Gandhi, H., Khan, Z., Tong, O., Katebifar, S., & Rajadhyaksha, M. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201848 · Cited by 1
“147 Although DRG toxicity is primarily a preclinical finding, select human rAAV clinical trials that have incorporated DRG assessments are discussed in the following section.”
Yu, Z., Li, Y., Zhang, Z., & Yin, R. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1901875
“Importantly, transgene detargeting from sensory neurons reduced dorsal-root-ganglion toxicity in nonhuman primates, showing that some adverse effects can be mitigated through product design rather than capsid selection alone (Hordeaux et al., 2020b).”
Nano Delivery Systems for In Vivo CRISPR/Cas-Based Gene Therapy: From Vectors to Clinical Outcomes
Chen, R., Zhou, H., Wu, Q., & Gong, C. (2026) · ACS Nano · doi:10.1021/acsnano.6c12154
CNS targeted AAV gene therapies: Recent advances and clinical insights
Brown, B. P., Lewis, R. W., Jr., & Davidson, B. L. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103118
Future directions and challenges of drug development and non-human primate models
Wang, Z., & Wu, X. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124768
Metadata
- Authors
- Hordeaux, J., Buza, E. L., Jeffrey, B., Song, C., Jahan, T., Yuan, Y., Zhu, Y., Bell, P., Li, M., Chichester, J. A., Calcedo, R., & Wilson, J. M.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Wilson, James M.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2020-11-11
- Volume
- 12
- Issue
- 569
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3104217413
- Cited by
- 174
- References
- 39
- Citations by year
- 2026: 25 · 2025: 27 · 2024: 32 · 2023: 37 · 2022: 26 · 2021: 25 · 2020: 1
- FWCI
- 13.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania Gene Therapy Program
- Orphan Disease Center (MPS-19-001-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- adeno-associated virus vectors, microRNA-183, transgene expression regulation, 3' untranslated region, non-human primates, central nervous system gene therapy, neurotoxicity, cisterna magna injection, steroid immunosuppression
- MeSH terms
- Dependovirus, Animals, Ganglia, Spinal, Genetic Vectors, Primates, Transduction, Genetic, Gene Transfer Techniques, Transgenes, MicroRNAs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.